نتایج جستجو برای: anti vegf

تعداد نتایج: 383792  

2014
Victoria L Bills Maryam Hamdollah-Zadeh Peter W Soothill Steven J Harper David O Bates

BACKGROUND Pre-eclampsia remains a dominant cause of maternal and fetal mortality in developed countries. In a previous prospective study we identified a fall in the VEGF-A isoform VEGF-A165b in the plasma of patients in the first trimester to be a predictor of later pre-eclampsia. VEGF-A165b has been shown to have potent cytoprotective properties in many cell types. We therefore tested the hyp...

Journal: :Frontiers in Medicine 2023

(PVR), macular degeneration, and retinitis pigmentosa (RP), can lead to blindness without timely treatment. Vascular endothelial growth factor (VEGF) has been identified as a key promoting vascular leakage angiogenesis, making neutralization of VEGF the first-line therapy for ischemic retinopathies such DR retinal occlusions. However, not all patients with these respond anti-VEGF therapy, neces...

2016
Peter Adamson Thomas Wilde Eric Dobrzynski Caroline Sychterz Rodd Polsky Edit Kurali Richard Haworth Chi-Man Tang Justyna Korczynska Fiona Cook Irene Papanicolaou Lemy Tsikna Chris Roberts Zoe Hughes-Thomas James Walford Daniel Gibson John Warrack Jos Smal Ruud Verrijk Paul E. Miller T. Michael Nork Jeffery Prusakiewicz Timothy Streit Steven Sorden Craig Struble Brian Christian Ian R. Catchpole

A potent anti-vascular endothelial growth factor (VEGF) biologic and a compatible delivery system were co-evaluated for protection against wet age-related macular degeneration (AMD) over a 6month period following a single intravitreal (IVT) injection. The anti-VEGF molecule is dimeric, containing two different anti-VEGF domain antibodies (dAb) attached to a human IgG1 Fc region: a dual dAb. The...

2016
Domenico Ribatti

Vascular endothelial growth factor (VEGF) has been identified as the most potent cytokine involved in tumor angiogenesis and metastasis formation. Clinical results of anti-angiogenic therapies targeting VEGF and its receptors are very modest, resulting in a moderate improvement of overall survival. The clinical outcome is associated with the development of resistance and the increased risk of i...

Journal: :Cancer research 2000
C G Lee M Heijn E di Tomaso G Griffon-Etienne M Ancukiewicz C Koike K R Park N Ferrara R K Jain H D Suit Y Boucher

Recent studies in experimental animals have shown that combining antiangiogenic therapy with radiation can enhance tumor response. Whether this enhancement is mainly attributable to angiogenesis inhibition, endothelial cell radiosensitivity, tumor cell apoptosis, or a decrease in the number of hypoxic cells (improved oxygenation) is not known. We designed this study to discern the role of tumor...

Journal: :Vision Research 2010
Hironori Uehara Ling Luo Jacquelyn Simonis Nirbhai Singh Ethan Will Taylor Balamurali K. Ambati

It is known that SPARC gates VEGF-A signal transduction towards KDR, the primary angiogenic VEGF receptor. We sought to determine whether inhibition of SPARC activity using anti-SPARC peptide could inhibit laser-induced CNV by promoting binding of VEGF-A to FLT-1. We created anti-SPARC l-peptide and retro-inverso anti-SPARC d-peptide. Anti-SPARC peptides or PBS were injected intravitreally 1day...

2017
Robert L. Avery Alessandro A. Castellarin Nathan C. Steinle Dilsher S. Dhoot Dante J. Pieramici Robert See Stephen Couvillion Ma'an A. Nasir Melvin D. Rabena Mauricio Maia Sherri Van Everen Kha Le William D. Hanley

PURPOSE To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). METHODS Prospective, open-label, nonrandomized clinical trial of patients with AMD, DME, or RVO who were antivascular endothelial growth factor (VEGF) naïve or ha...

2012
Ilias Zampros Anna Praidou Periklis Brazitikos Panagiotis Ekonomidis Sofia Androudi

Age-related macular degeneration (AMD) is the leading cause of severe visual loss and blindness over the age of 50 in developed countries. Vascular endothelial growth factor (VEGF) is considered as a critical molecule in the pathogenesis of choroidal neovascularization (CNV), which characterizes the neovascular AMD. Anti-VEGF agents are considered the most promising way of effectively inhibitio...

Journal: :Oncology reports 2007
T Okunaka J Usuda S Ichinose H Hirata K Ohtani S Maehara T Inoue K Imai M Kubota Y Tsunoda Y Kuroiwa H Tsutsui K Furukawa K Nishio H Kato

ATX-s10-Na(II) is a novel second-generation photo-sensitizer for photodynamic therapy (PDT). PDT using ATX-s10 and diode laser (670 nm) induces an apoptotic response, inflammatory reaction, immune reaction and damage to the microvasculature. In particular, the vascular shut-down effect plays an important role in the anti-tumor activity of ATX-s10-PDT. It has been reported that PDT induces hypox...

2016
Dianbao Zhang Xianfen Zhang Chunling Zhao

AIMS To assess the incidence and risk of arterial and venous thromboembolic events (ATEs and VTEs) associated with antivascular endothelial growth factor (VEGF) agents, including VEGF receptor-tyrosine kinase inhibitors and VEGF monoclonal antibodies, in advanced non-small-cell lung cancer (NSCLC) patients. METHODS We performed a broad search of PubMed for relevant trials. Prospective randomi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید